KAZIA THERAPEUTICS LTD
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$55M
Investors
65
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
KAZIA THERAPEUTICS LTD is a Australia corporation that filed a Form D with the SEC on December 18, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. KAZIA THERAPEUTICS LTD reported $55,251,088 sold from 65 investors of a $55,251,088 total offering as of the Form D filed December 18, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names T.R. Winston & Company LLC (CRD 10571), associated with Konik Capital Partners LLC as the recipient of sales compensation soliciting in AZ, CA, CO, CT, DE, FL, GA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MT, NJ, NV, NY, OH, OR, PA, PR, SD, TN, TX, UT, WA, WY. Sales commissions are reported as $3,328,063 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is Three International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, 2000.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
3
latest Dec 18, 2025
Critical / warning
0 / 0
1 watch · 2 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
closed
Latest event New filer · Dec 18, 2025
SEC.govInvestor
- 3 filing events with values and deltas, latest 2025-12-18, and alerts on the next one
- 4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
John Friend
Executive Officer · Sydney, C3
Bryce Carmine
Director · Sydney, C3
Steven Coffey
Director · Sydney, C3
Ebru Davidson
Director · Sydney, C3
Robert Apple
Director · Sydney, C3
Jeffrey Bonacorda
Executive Officer · Sydney, C3
Elissa Hansen
Executive Officer · Sydney, C3
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
T.R. Winston & Company LLCCRD 10571 on BrokerCheck
Associated broker-dealer: Konik Capital Partners LLC · New York, NY · Soliciting in AZ, CA, CO, CT, DE, FL, GA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MT, NJ, NV, NY, OH, OR, PA, PR, SD, TN, TX, UT, WA, WY and outside the United States
Questions About KAZIA THERAPEUTICS LTD
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is KAZIA THERAPEUTICS LTD?
KAZIA THERAPEUTICS LTD is a Australia corporation that filed a Form D with the SEC on December 18, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is KAZIA THERAPEUTICS LTD legit?
AltStreet does not rate legitimacy; it reports the public record. KAZIA THERAPEUTICS LTD filed a Form D with the SEC on December 18, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $55,251,088 sold to 65 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is KAZIA THERAPEUTICS LTD registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that KAZIA THERAPEUTICS LTD claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has KAZIA THERAPEUTICS LTD raised?
KAZIA THERAPEUTICS LTD reported $55,251,088 sold from 65 investors of a $55,251,088 total offering as of the Form D filed December 18, 2025.
Who can invest in KAZIA THERAPEUTICS LTD?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in KAZIA THERAPEUTICS LTD?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling KAZIA THERAPEUTICS LTD and how are they paid?
The Form D names T.R. Winston & Company LLC (CRD 10571), associated with Konik Capital Partners LLC as the recipient of sales compensation soliciting in AZ, CA, CO, CT, DE, FL, GA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MT, NJ, NV, NY, OH, OR, PA, PR, SD, TN, TX, UT, WA, WY. Sales commissions are reported as $3,328,063 and finders' fees as $0. Form D allows these to be estimates.
Who is behind KAZIA THERAPEUTICS LTD?
The Form D lists 7 related persons: John Friend, executive officer; Bryce Carmine, director; Steven Coffey, director; Ebru Davidson, director; Robert Apple, director; Jeffrey Bonacorda, executive officer; Elissa Hansen, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is KAZIA THERAPEUTICS LTD located?
The issuer's address on its SEC filings is Three International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, 2000. Its phone number of record is 01161298780088. It is organized under the laws of Australia.
How long is the KAZIA THERAPEUTICS LTD offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is KAZIA THERAPEUTICS LTD's revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
